One of the most common oral antidiabetic medications is metformin, the first-line drug of choice for type 2 diabetes, especially in people who are overweight. Compared to other oral antidiabetic drugs, Metformin has fewer side effects and is found to prevent the cardiovascular complications of type 2 diabetes, such as strokes and heart attacks.
According to research, metformin also decreases the risk of diabetes-related endpoints in overweight people diagnosed with type 2 diabetes. Additionally, it is associated with fewer hypoglycemic attacks and less weight gain than other type 2 diabetes medications such as insulin and sulfonylureas, considering that it has a similar effect on blood sugar control with the other two drugs mentioned.
However, like any other medications, metformin has contraindications including liver disease, kidney disease, congestive heart failure, and severe infection. It is vital for you to notify the physician before he/she prescribes metformin because you may develop lactic acidosis, which is a life-threatening condition.
With diabetes now considered pandemic throughout the world, there have been enormous advances in the field since the last edition of Diabetes For Dummies. Now significantly revised and updated, it includes the latest information on medications and monitoring equipment, updated diet and exercise plans, new findings about treating diabetes in the young and elderly, new ways to diagnose and treat long- and short-term complications, and more.
Want to know how to manage diabetes? Trusted diabetes expert Dr. Alan Rubin gives you reassuring, authoritative guidance on putting together a state-of-the-art treatment program to treat diabetes successfully and live a full life. You’ll learn about all the advances in monitoring glucose, the latest medications, and how to develop a diet and exercise plan to stay healthy.
Diabetes For Dummies is for the millions of Diabetics(and their loved ones) throughout the United States who are in search of a resource to help them manage this disease.